NCT01593735View on ClinicalTrials.gov

A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Hepatitis C
Interventions
DRUG

MK-2748

MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment

DRUG

Placebo

Placebo tablets, orally, once daily for 7 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01593735 - A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) | Biotech Hunter | Biotech Hunter